Investors & Media

Webcast ImageWebcast
Q1 2017 Ionis Pharmaceuticals Inc Earnings Conference Call (Live)
05/09/17 at 11:30 a.m. ET
Q1 2017 Ionis Pharmaceuticals Inc Earnings Conference Call
Tuesday, May 9, 2017 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
DateTitle
04/26/17Ionis Pharmaceuticals to Hold First Quarter 2017 Financial Results Webcast
Webcast scheduled for Tuesday, May 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif., April 26, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, May 9 at 11:30 a.m. Eastern Time to discuss its first quarter 2017 financial results and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. ... 
04/24/17Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
      Presymptomatic Infants Continued to Achieve Motor Milestones Generally Consistent with Normal Development in New Interim Data Analysis    Positive Data Across a Broad Range of Individuals with SMA Presented at the American Academy of Neurology Annual Meeting    April 24, 2017 07:30 AM Eastern Daylight Time      CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) will present Phase 3 end of study SPINRAZA®(nusinersen) data from CHERISH, ... 
04/21/17Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
First SMA Treatment Recommended for Approval in the EU CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 21, 2017-- Biogen (NASDAQ: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a marketing authorization for SPINRAZA® (nusinersen) to treat patients with spinal muscular atrophy (SMA). The CHMP reviewed SPINRAZA under an accelerated assessment program, which is a regulatory mech... 
04/18/17Ionis Enters into Collaboration with Ribo to Advance RNA-Targeted Therapeutics in China
- Ionis gains a key partner in China to develop up to three Generation 2+ antisense drugs in metabolic disease and cancer - Ribo to commit significant resources to advance Ionis' single-stranded RNAi (ssRNAi) technology - Ionis retains rights to develop and commercialize ssRNAi technology and all drugs under the collaboration outside of China CARLSBAD, Calif., April 18, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced a collaboration and license agreement ... 
Upcoming EventsMore >>
DateTitle
04/27/17
through
04/28/17
AAN 2017 Annual Meeting
Supporting Materials
Download Event Supporting Material AAN Presentation Summary
Download Event Supporting Material AAN CHERISH Presentation/Poster
Download Event Supporting Material AAN ENDEAR Presentation
05/09/17 11:30 a.m. ET
Q1 2017 Ionis Pharmaceuticals Inc Earnings Conference Call
Supporting Materials
05/24/17 2:00 p.m. PT
Annual Stockholder Meeting & Open House
Supporting Materials

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.